1.17%
-15.53%
-29.27%
-38.30%
-42.76%
-92.67%
-90.55%
AI Spotlight on SPRO
Company Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.It has license agreement with Meiji Seika Pharma Co., Ltd.
to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 0.87 |
| Change Percentage | 1.17% |
| Open | 0.85 |
| Previous Close | 0.86 |
| Market Cap ( Millions) | 47 |
| Volume | 149445 |
| Year High | 1.89 |
| Year Low | 0.83 |
| M A 50 | 1.04 |
| M A 200 | 1.29 |
Financial Ratios
| FCF Yield | -36.97% |
| Dividend Yield | 0.00% |
| ROE | 3.36% |
| Debt / Equity | 7.06% |
| Net Debt / EBIDTA | 7371.36% |
| Price To Book | 0.72 |
| Price Earnings Ratio | 16.05 |
| Price To FCF | -2.7 |
| Price To sales | 0.53 |
| EV / EBITDA | 24.93 |
News
- Jan -19 - Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
- Jan -15 - Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know
- Jan -10 - Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
- Dec -17 - Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Nov -15 - New Strong Buy Stocks for November 15th
- Nov -14 - Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
- Nov -14 - Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
- Oct -16 - Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
- Oct -02 - Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
- Aug -09 - Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
- Aug -05 - Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
- Aug -05 - Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
- Jul -29 - Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
- Jul -08 - 3 Micro-Cap Moonshots for Fearless Investors
- Jul -03 - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jun -03 - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- May -20 - HC Wainwright Brokers Boost Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO)
- May -16 - Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
- May -15 - Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
- May -08 - Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Treatments for Multi-drug Resistant Bacterial Infections
Expected Growth : 3.0 %
What the company do ?
Spero Therapeutics, Inc. develops novel treatments for multi-drug resistant bacterial infections, including oral antibiotics and IV-administered therapies to combat antimicrobial resistance.
Why we expect these perspectives ?
Spero Therapeutics' novel treatments for multi-drug resistant bacterial infections drive 3.0% growth, fueled by increasing antibiotic resistance, rising healthcare costs, and growing demand for effective infection treatments. Strong pipeline, strategic partnerships, and regulatory support also contribute to growth.
Spero Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Tebipenem HBr | An oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). |
| SPR720 | An oral antibiotic being developed for the treatment of non-tuberculous mycobacterial (NTM) lung disease. |
| SPR206 | An intravenous (IV) antibiotic being developed for the treatment of multidrug-resistant (MDR) Gram-negative bacterial infections. |
| SPR741 | An oral antibiotic being developed for the treatment of MDR Gram-negative bacterial infections. |
Spero Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Spero Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the pharmaceutical industry.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Spero Therapeutics, Inc.'s products, which are often prescribed by healthcare professionals.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers in the market, but Spero Therapeutics, Inc.'s dependence on a few critical suppliers increases their bargaining power.
Threat Of New Entrants
The threat of new entrants is high due to the growing demand for antibiotics and the increasing investment in research and development in the pharmaceutical industry.
Intensity Of Rivalry
The intensity of rivalry is moderate due to the presence of several established players in the market, but Spero Therapeutics, Inc.'s focus on niche areas reduces the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.93% |
| Debt Cost | 3.95% |
| Equity Weight | 95.07% |
| Equity Cost | 7.04% |
| WACC | 6.89% |
| Leverage | 5.19% |
Spero Therapeutics, Inc. : Quality Control
Spero Therapeutics, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MEIP | MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta … |
| INVA | Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol … |
| CPRX | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, … |
| HRTX | Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Innoviva
A-Score
1-Year Total Return ->
🥈
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
MEI Pharma
A-Score
1-Year Total Return ->
4
Spero Therapeutics
A-Score
1-Year Total Return ->
5
Heron Therapeutics
A-Score
1-Year Total Return ->
6
